Search
Briacell Therapeutics Corp
BCTXAdd to Watchlist
3.440USD
-0.190-5.23%
Close 07-31 16:00（ET）Quotes delayed by 15 min
29.92MMarket Cap
LossP/E TTM
More Details of Briacell Therapeutics Corp Company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Briacell Therapeutics Corp Info
Ticker SymbolBCTX
Company nameBriacell Therapeutics Corp
IPO dateOct 12, 2006
CEOWilliams (William V)
Number of employees22
Security typeOrdinary Share
Fiscal year-endOct 12
AddressSuite 300 - Bellevue Centre, 235 -15th Street
CityWEST VANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV7T 2X1
Phone16049211810
Websitehttps://briacell.com/
Ticker SymbolBCTX
IPO dateOct 12, 2006
CEOWilliams (William V)
Company Executives of Briacell Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.90K
+98.69%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
56.52K
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
28.27K
+99.94%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
28.26K
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
66.00
--
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
--
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.90K
+98.69%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
56.52K
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
28.27K
+99.94%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
28.26K
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
--
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
66.00
--
FAQs
Who are the top five shareholders of Briacell Therapeutics Corp?
The top five shareholders of Briacell Therapeutics Corp are: Dr. William V. Williams, M.D.
How many institutions hold shares of Briacell Therapeutics Corp (BCTX)?
As of 2026Q1, 52 institutions hold shares of Briacell Therapeutics Corp, with a combined market value of approximately 155.47K, accounting for 2.14% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -64567.00.